20 February 2018

ASX ANNOUNCEMENT

Stage II success for new manufacturing technology: Lidocaine

Medical Developments International Limited (ASX: MVP) is delighted to announce that, in partnership with the CSIRO, it has successfully completed a small-scale production run for Lidocaine using MVP's new manufacturing technology.

Lidocaine has worldwide sales of approximately $3.4 billion. It is a common local anaesthetic and antiarrhythmic drug. It is injected as a local anaesthetic for minor surgery and used as a dental anaesthetic.

For the full release, please refer to the following link ASX Announcement - Stage II success for new manufacturing technology - Lidocaine

Medical Developments International Limited published this content on 20 February 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 20 February 2018 01:30:03 UTC.

Original documenthttp://www.medicaldev.com/news/stage-ii-success-new-manufacturing-technology-lidocaine/

Public permalinkhttp://www.publicnow.com/view/4AB43EB574EA3A6E5FD44E96319D04A7779D298B